Donald L. Siegel, MD, PhD

faculty photo
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Department: Pathology and Laboratory Medicine

Contact information
9-112 South Tower, Big 421
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215) 662-3942
Lab: (215) 898-9655
Sc.B. (Biophysics)
Brown University, 1977.
Ph.D. (Biophysics)
Harvard University, 1983.
University of Pennsylvania, 1987.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Research Interests

Discovery and characterization of diagnostic and therapeutic monoclonal antibodies

Research Summary

My laboratory studies human immune repertoires in health and disease using phage display technologies for the production of human and non-human monoclonal antibodies relevant to transfusion medicine, benign hematology, infectious diseases, and oncology. Current studies focus on developing targeted drug delivery methods using red cell antibodies coupled to novel anti-thrombotic/anti-inflammatory molecules; cloning monoclonal primate neutralizing Dengue, Ebola, MERS and Zika virus antibodies for human in vivo antibody gene expression therapy; and isolating recombinant human and humanized antibody fragments for the design of T-cell chimeric antigen receptors for cancer therapy.

Description of Clinical Expertise

transfusion medicine, blood banking, apheresis, hematopoietic stem cell collection/processing, cGMP manufacture of cellular therapies for phase I first-in-human clinical trials

Selected Publications

Tebas, P., Jadlowsky, J., Shaw, P., Lee, G., Ando, D., Kim, S., Naing, S.Y., Lacey, S., Levine, B.L., Siegel, D.L., June, C.H., Riley, J.L. : Delayed Viral rebound during ATI after infusion of CCR5 ZFN-treated CD4 T cells. 2019 Conference on Retroviruses and Opportunistic Infections (CROI) 2019.

Villa, C.H., Pan, D.C., Johnston, I., Greineder, C.F., Walsh, L., Hood, E., Cines, D.B., Poncz, M., Siegel, D.L., Muzykantov, V.R.: Biocompatible coupling of therapeutic fusion proteins to human erythrocytes. Blood Advances 2: 165-176, 2018.

Gill, S.I., Vides, V., Frey, N.V., Metzger, S., O'Brien, M., Hexner, E., Mato, A.R., Lacey, S.F., Melenhorst, J.J., Pequignot, E., Gladney, W.L., Hwang, W-T, Lamontagne, A., Davis, M., Byrd, J.C., Schuster, S.J., Siegel, D.L., Isaacs, R.E., June, C.H., Porter, D.L. : Prospective clinical trial of anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate. Blood 132: 298, 2018.

Hammers, C.M., Yuan, H., Lin, C., Tang, H.Y., Siegel, D.L., Stanley, J.R. : Cloning and analysis of bullous pemphigoid anti-BP180 IgG and IgE autoantibodies indicates predominance of VL1-47 gene usage and direct (from IgM) and indirect (through IgG) class switching to IgE. Exp Dermatol 27: E64-E65, 2018.

Dancy, E., Garfall, A.L., Cohen, A.D., Fraietta, J.A., Davis, M., Levine, B.L., Siegel, D.L., Stadtmauer, E.A., Vogl, D.T., Waxman, A., Rapoport, A.P., Milone, M.D., June, C.H., Melenhorst, J.J.: Clinical predictors of T cell fitness for CAR T cell manufacturing and efficacy in multiple myeloma. Blood 132: 1886, 2018.

Chong, E.A., Levine, B.L., Grupp, S.A., Davis, M., Siegel, D.L., Maude, S.L., Gladney, W.L., Frey, N.V., Porter, D.L., June, C.H., Schuster, S.J.: CD19-directed CAR T-cell (CTL019) product viability and clinical outcomes in non-Hodgkin lymphomas and B-cell acute lymphoblastic leukemia. Blood 132: 197, 2018.

Nobles, C.L., Everett, J.K., Reddy, S., Fraietta, J.A., Porter, D.L., Frey, N.V., Grupp, S.A., Siegel, D.L., Lacey, S.F., June, C.H., Bushman, F.D., Melenhorst, J.J. : Vector integration and efficacy of CD19-directed CAR T cell therapy in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). Blood 132: 4548, 2018.

Garfall, A., Stadtmauer, E., Hwang, W.-T., Lacey, S., Melenhorst, J., Krevvata, M., Carroll, M., Matsui, W., Wang, Q., Dhodapkar, M., Dhodapkar,K., Das, R., Vogl, D., Weiss, B., Cohen, A., Mangan, P., Ayers, E., Nunez-Cruz , S., Kulikovskaya, I., Davis, M., Lamontagne, A., Dengel, K., Kerr, N., Young, R., Siegel, D.L., Levine, B., Milone, M.C., Maus, M., June, C.H.: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3: e120505, 2018.

Robust automated cell counter and viability measurement for engineered T cell product release,: Ohayon, Y., Corl, C.M., Leskowitz, R.M., Malykhin, A., Arostegui, S.M., Hennesy, N.A, Ngo, S., Levine, B.L., Siegel, D.L., Fesnak, A., Davis, M.M. Cytotherapy 20: S69, 2018.

Fraietta, J.A., Lacey, S.F., Orlando, E.J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A.C., Wang, Y., O'Connor, R.S., Hwang, W.-T., Pequignot, E., Ambrose, D.E., Zhang, C., Wilcox, N., Bedoya, F., Dorfmeir, C., Chen, F., Tian, L., Parakandi, H., Gupta, M., Young, R.M., Johnson, F.B., Kulikovskaya, I., Liu, L., Xu, J., Kassim, S.H., Suhoski-Davis, M.M., Levine, B.L., Frey, N.V., Siegel, D.L., Huang, A.C., Wherry, E.J., Bitter, H., Brogdon, J.L., Porter, D.L., June, C.H., Melenhorst, J.J: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine 24: 563-571, 2018.

back to top
Last updated: 01/05/2019
The Trustees of the University of Pennsylvania